Loading chart data...
Maravai LifeSciences is exploding higher today, mirroring a massive surge across the biotechnology sector that has seen major players like Moderna and BioNTech post significant gains. No company-specific news has been released in the last 48 hours to account for this move, suggesting that the stock is rallying in sympathy with a broader industry-wide rotation or a positive macro shift affecting RNA-focused life science companies. With peers like TEM and BNTX also seeing double-digit percentage increases, the price action appears to be driven by a strong sector-wide tailwind rather than individual corporate developments.
That explains the day. Whether MRVI is a business worth owning is a longer question. Koyfin has the ten-year financials, margin history and valuation to answer it — 20% off for WhyTheMove readers.
No significant catalyst events detected.
No recent news for MRVI.